51
Participants
Start Date
January 5, 2023
Primary Completion Date
June 1, 2024
Study Completion Date
June 1, 2024
18F Fluoroestradiol Radiopharmaceutical with PET/CT
Administration of one dose of 18F FES for PET/CT imaging
Icahn School of Medicine at Mount Sinai, New York
The New York Presbyterian Hospital-Columbia University Medical Center, New York
Magee-Womens Hospital of UPMC, Pittsburgh
St. Luke's University Health Network, Allentown
University of Pennsylvania / Perelman Center for Advanced Medicine, Philadelphia
University of Virginia, Charlottesville
Blue Ridge Cancer Care, Roanoke
WakeMed, Cary
Duke University, Durham
Emory University, Atlanta
Tampa General Hospital Cancer Institute, Tampa
Kettering Health Cancer Center, Kettering
MD Clinics, Shreveport
Baylor Research Institute d/b/a Baylor Scott & White Research Institute, Dallas
Northern Arizona Healthcare, Flagstaff
University of Southern California, Los Angeles
Providence Saint John's Health Center, Santa Monica
TOI Clinical Research, Cerritos
Long Beach Memorial Medical Center, Long Beach
City of Hope Comprehensive Cancer Center, Duarte
Valley Breast Care, Van Nuys
Hoag Memorial Hospital Presbyterian, Newport Beach
PET/CT Imaging of San Jose, San Jose
Fred Hutchinson Cancer Center, Seattle
Lead Sponsor
Collaborators (3)
Simbec-Orion Group
INDUSTRY
Medpace, Inc.
INDUSTRY
Zionexa
INDUSTRY
GE Healthcare
INDUSTRY